Biologics CDMO companies

Report ID: 5516
Published Date: Sep 16, 2025
Report Format: PDF, PPT

Buy Now

Biologics CDMO Market Players:

Key companies in the biologics CDMO market are innovating by investing in advanced technologies such as cell and gene therapies, AI-driven process optimization, and state-of-the-art processing capabilities. They focus on enhancing bio-engineered assembly through scalable, efficient, and cost-effective solutions. Additionally, they are forming strategic partnerships to strengthen their service offerings and expand their geographic presence. For instance, in February 2024, Eurofins CDMO Alphora Inc. empowered its market grip by combining expertise in API/HPAPI with advanced biologics capacity and enhancing development capabilities through its new pilot-scale facility. Such innovations accelerate drug development and increase capacity. Some of these key companies are:

3P Biopharmaceuticals
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
AbbVie Inc.
AGC Biologics
Binex Co. Ltd.
Boehringer Ingelheim International GmbH
Bora Pharmaceuticals
Kemwell Biopharma Pvt. Ltd.
Lonza Group Ltd.
Novartis AG
Eurofins Scientific
Rentschler Biopharma SE

Browse key industry insights with market data tables & charts from the report:

Biologics CDMO Market Size, Share & Growth Outlook to 2035

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of biologics CDMO is assessed at USD 23.54 billion.

The global biologics CDMO market size was valued at over USD 21.02 billion in 2025 and is expected to register a CAGR of around 13.3%, exceeding USD 73.27 billion revenue by 2035.

The North America biologics cdmo market will dominate more than 37.10% share by 2035, driven by the development of cutting-edge therapies like gene editing and cell therapies, alongside increasing prevalence of chronic diseases, cancer, and autoimmune disorders.

Key players in the market include Lonza Group AG, Catalent, Inc., Samsung Biologics Co., Ltd., WuXi Biologics (Cayman) Inc., Boehringer Ingelheim International GmbH, Fujifilm Diosynth Biotechnologies, Patheon (Thermo Fisher Scientific), AGC Biologics, Cytiva (Danaher Corporation), Rentschler Biopharma SE.